HomeAI · summaries
Storia in 3 fonti
Hims & Hers abandons copycat weight-loss drug in face of FDA probe
Novo Nordisk had accused the telehealth company of breaching its patent on Wegovy
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
cnbc.com
Novo Nordisk and Eli Lilly fall after Hims & Hers announce $49 copy of Wegovy pill
Novo Nordisk and Eli Lilly fell after Hims & Hers said it will offer a copy of the Wegovy pill for $49, far less than the $149 Novo sells the branded pill for.
- ·
ft.com
Novo Nordisk hits out at rival Hims & Hers over cheaper weight-loss pill
US telehealth group will sell product for $49 a month, a third that of its Danish competitor
- ·
White House launches TrumpRx as drug companies warn of sales hit
Platform offers discounts for weight-loss and fertility medicines sold by Novo Nordisk, Eli Lilly and others
- ·
Hims & Hers abandons copycat weight-loss drug in face of FDA probe
Novo Nordisk had accused the telehealth company of breaching its patent on Wegovy
- ·
Novo Nordisk faces more gloom from price cuts in crowded anti-obesity drugs market
Danish group’s challenges mount despite winning reprieve after Hims & Hers withdraws plan to sell copycat Wegovy pill
- ·
Novo Nordisk sues Hims & Hers over copycat weight-loss drugs
Shares in US company fall 16% after FDA announces investigation into unregulated medication
- ·
upi.com
Novo Nordisk suing Hims & Hers over ‘copycat’ weight loss drug - UPI.com
Novo Nordisk, the maker of the weight loss drug Wegovy, is suing Hims & Hers for selling a cheaper version of the drug, the company announced Monday.